Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Factors that aid survival of prostate cancer cells in the presence of the various categories of cytotoxic cytokines present in tumors in vivo are largely unknown. Osteoprotegerin (OPG) is a decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that inhibits TRAIL-induced...

Полное описание

Библиографические подробности
Главные авторы:	Holen, I, Croucher, P, Hamdy, F, Eaton, C
Формат:	Journal article
Язык:	English
Опубликовано:	2002

Схожие документы

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
по: Eaton, C, и др.
Опубликовано: (2004)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
по: Eaton, C, и др.
Опубликовано: (2004)

OPG is a survival factor for breast- and prostate cancer cells in vitro
по: Holen, I, и др.
Опубликовано: (2002)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
по: Holen, I, и др.
Опубликовано: (2002)

Role of osteoprotegerin (OPG) in cancer.
по: Holen, I, и др.
Опубликовано: (2006)

The role of osteoprotegerin in breast and prostate cancer
по: Holen, I, и др.
Опубликовано: (2002)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
по: Holen Ingunn, и др.
Опубликовано: (2009-07-01)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
по: Shipman, C, и др.
Опубликовано: (2002)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
по: Lili Zhang, и др.
Опубликовано: (2016-11-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
по: Shipman, C, и др.
Опубликовано: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
по: Shipman, C, и др.
Опубликовано: (2000)

Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome
по: Gamal B Mohamed, и др.
Опубликовано: (2011-01-01)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
по: Waterman, E, и др.
Опубликовано: (2007)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
по: Miles, L, и др.
Опубликовано: (2004)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
по: Croucher, P, и др.
Опубликовано: (2000)

Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells
по: Noura N. Alraouji, и др.
Опубликовано: (2024-08-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
по: Riham Eid, и др.
Опубликовано: (2023-06-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
по: Shipman, C, и др.
Опубликовано: (2003)

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
по: Siamak Kazemi-Sufi, и др.
Опубликовано: (2024-09-01)

Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis
по: Nyambo, R, и др.
Опубликовано: (2004)

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
по: Nyambo, R, и др.
Опубликовано: (2004)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
по: Chan Kai-Ming, и др.
Опубликовано: (2011-07-01)

Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease
по: Syed Muhammad Muneeb Akhtar, и др.
Опубликовано: (2024-07-01)

Osteoprotegerin and the development of myeloma bone disease
по: Croucher, P, и др.
Опубликовано: (2004)

Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts
по: Yao Jing, и др.
Опубликовано: (2011-03-01)

Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
по: Saba Tariq, и др.
Опубликовано: (2022-02-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
по: Yosra Azizpour, и др.
Опубликовано: (2020-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
по: Yosra Azizpour, и др.
Опубликовано: (2020-01-01)

The survival effect of prolactin on PC3 prostate cancer cells.
по: Ruffion, A, и др.
Опубликовано: (2003)

Involvement of FXR in the OPG/RANKL pathway of breast and prostate cancer cells
по: Lara Absil, и др.
Опубликовано: (2021-04-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
по: Indra Wijaya, и др.
Опубликовано: (2024-01-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
по: Croucher, P, и др.
Опубликовано: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
по: Croucher, P, и др.
Опубликовано: (2001)

Determinant Factors and Added Value of Osteoprotegerin (OPG) to Detect Carotid Intima-Media Thickness (CIMT) in Type 2 Diabetes Mellitus Patient
по: Shirly Elisa Tedjasaputra, и др.
Опубликовано: (2018-06-01)

Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids
по: Salvador Atilano-Miguel, и др.
Опубликовано: (2022-01-01)

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis
по: Lane Denis, и др.
Опубликовано: (2012-11-01)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
по: Martin Widschwendter, и др.
Опубликовано: (2015-10-01)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells
по: Cross, N, и др.
Опубликовано: (2008)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells.
по: Cross, N, и др.
Опубликовано: (2008)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
по: Vanderkerken, K, и др.
Опубликовано: (2003)